Your browser doesn't support javascript.
loading
Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
Cheng, Qi; Cheng, Jinluo; Cordato, Dennis; Gao, Jianqun.
Afiliação
  • Cheng Q; Department of Neurology and Neurophysiology, Liverpool Hospital, Sydney, New South Wales, Australia; Stroke and Neurology Research Group, Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.
  • Cheng J; Department of Endocrinology, Changzhou No.2 People's Hospital, Nanjing Medical University, Changzhou, China.
  • Cordato D; Department of Neurology and Neurophysiology, Liverpool Hospital, Sydney, New South Wales, Australia; Stroke and Neurology Research Group, Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.
  • Gao J; Brain and Mind Centre, Central Clinical School, the University of Sydney, Sydney, Australia. Electronic address: drgaojqun@icloud.com.
Pharmacol Ther ; 212: 107559, 2020 08.
Article em En | MEDLINE | ID: mdl-32380197
The linkage of neurodegenerative diseases with insulin resistance (IR) and type 2 diabetes mellitus (T2DM), including oxidative stress, mitochondrial dysfunction, excessive inflammatory responses and abnormal protein processing, and the correlation between cerebrovascular diseases and hyperglycemia has opened a new window for novel therapeutics for these cognitive disorders. Various antidiabetic agents have been studied for their potential treatment of cognitive disorders, among which the dipeptidyl peptidase-4 (DPP-4) inhibitors have been investigated more recently. So far, DPP-4 inhibitors have demonstrated neuroprotection and cognitive improvements in animal models, and cognitive benefits in diabetic patients with or without cognitive impairments. This review aims to summarize the potential mechanisms, advantages and limitations, and currently available evidence for developing DPP-4 inhibitors as a treatment of cognitive disorders.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Inibidores da Dipeptidil Peptidase IV / Disfunção Cognitiva Limite: Animals / Humans Idioma: En Revista: Pharmacol Ther Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Inibidores da Dipeptidil Peptidase IV / Disfunção Cognitiva Limite: Animals / Humans Idioma: En Revista: Pharmacol Ther Ano de publicação: 2020 Tipo de documento: Article